Skip to content
Children's Cancer Therapy Development Institute
  • Home
  • Pipeline
  • About
    • Our Mission
    • Team Members
    • Alumni
    • Our Blog
    • Mission In Motion
    • In the Press
    • Supporters
    • Financials
  • Resources
    • Support
    • Awareness
    • Childhood Cancer
      • Ewing Sarcoma
  • Research
    • Active Research Projects
    • CuRe-FAST Program
    • Machine Learning
    • Myoepithelial Carcinoma (MEC)
    • Nanocourse for Families
    • Projects Needing Funding
    • Publications
  • Get Involved
    • Fundraise with cc-TDI
    • Junior Board
  • Honor Pages
  • New Lab!
  • Donate Now
    • Matching Gifts
    • Donor Advised
    • Donation History
Menu Close
  • Home
  • Pipeline
  • About
    • Our Mission
    • Team Members
    • Alumni
    • Our Blog
    • Mission In Motion
    • In the Press
    • Supporters
    • Financials
  • Resources
    • Support
    • Awareness
    • Childhood Cancer
      • Ewing Sarcoma
  • Research
    • Active Research Projects
    • CuRe-FAST Program
    • Machine Learning
    • Myoepithelial Carcinoma (MEC)
    • Nanocourse for Families
    • Projects Needing Funding
    • Publications
  • Get Involved
    • Fundraise with cc-TDI
    • Junior Board
  • Honor Pages
  • New Lab!
  • Donate Now
    • Matching Gifts
    • Donor Advised
    • Donation History

Blog Posts

needs funding

Back to All Blog Posts

Epithelioid Sarcoma Target & Drug Identification: $120,000 annually

admin November 28, 2018

Expanding Chemical Space

A Radiation Synthetic Combination for Osteosarcoma Local Control: $100,000 annually

admin November 28, 2018

Be the sponsor of this project! Osteosarcoma is a disease for which local control can be critical:  for tumors in a limb, local control permits

CureFast: Creating a Legacy by Accelerating Childhood Cancer Research: $156,000 annually

admin November 28, 2018

Be the sponsor of this project!  One in 5 children with cancer will not survive. We propose to address gaps in basic and translational research

Marizomib in Medulloblastoma: $240,000 over 2 years

admin November 28, 2018

The goal of this preclinical study is to validate marizomib as a treatment for medulloblastoma.

Dupixent as an anti-metastasis agent for Rhabdomyosarcoma: $240,000 over 2 years

admin November 28, 2018

Be the sponsor of this project! What if an FDA-approved dermatitis and asthma medicine could stop rhabdomyosarcoma metastasis?  The major goal of this project is

The IL13RA2-HAS2 axis as therapeutic co-targets in DIPG: $249,000 over 2 years

admin November 28, 2018

Be the sponsor for this project! We have investigated presence of the IL13RA2 protein in DIPG, and we have shown there is 13 times higher

Epithelioid Sarcoma Target & Drug Identification: $120,000 annually

admin November 28, 2018

Expanding Chemical Space

A Radiation Synthetic Combination for Osteosarcoma Local Control: $100,000 annually

admin November 28, 2018

Be the sponsor of this project! Osteosarcoma is a disease for which local control can be critical:  for tumors in a limb, local control permits

CureFast: Creating a Legacy by Accelerating Childhood Cancer Research: $156,000 annually

admin November 28, 2018

Be the sponsor of this project!  One in 5 children with cancer will not survive. We propose to address gaps in basic and translational research

Marizomib in Medulloblastoma: $240,000 over 2 years

admin November 28, 2018

The goal of this preclinical study is to validate marizomib as a treatment for medulloblastoma.

Dupixent as an anti-metastasis agent for Rhabdomyosarcoma: $240,000 over 2 years

admin November 28, 2018

Be the sponsor of this project! What if an FDA-approved dermatitis and asthma medicine could stop rhabdomyosarcoma metastasis?  The major goal of this project is

The IL13RA2-HAS2 axis as therapeutic co-targets in DIPG: $249,000 over 2 years

admin November 28, 2018

Be the sponsor for this project! We have investigated presence of the IL13RA2 protein in DIPG, and we have shown there is 13 times higher

Recent Posts

  • Re-invest in Research
  • 10 Year Impact Report!
  • cc-TDI Partners with NIH on RMS
  • Our hero, Abby: A Parent’s Heartfelt Journey
  • 2025 Summer Internship Opportunities!

Categories

  • Announcements
  • Family Partners
  • Fundraising
  • Nanocourse
  • Open Science
  • Research
  • Science Non-Fiction
  • Team

Subscribe

Get our quarterly update delivered straight to your email!
Email is required Email is not valid
Thanks for your subscription.
Failed to subscribe, please contact admin.

Follow Us

  • Opens in a new tab
  • Opens in a new tab
  • Opens in a new tab

Navigation

  • Home
  • Our Mission
  • Team Members
  • Blog
  • Get Involved
  • Careers
  • Home
  • Our Mission
  • Team Members
  • Blog
  • Get Involved
  • Careers

Contact

  • 9025 NE Von Neumann Dr. Suite 110, Hillsboro, OR 97006
  • (503) 985-6016
  • info@cc-tdi.org
Sign Up for Email or Text Updates

More Information

EIN: 46-5759569

cc-TDI is a qualified 501(c)(3) charitable organization registered with the IRS
(consult with a CPA regarding specific tax implications)

 

Copyright 2024 – Children’s Cancer Therapy Development Institute